RCM
OBIO icon

Radcliffe Capital Management’s Orchestra BioMed OBIO Stock Holding History

Radcliffe Capital Management’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-407,563
Closed -$4.06M – 1198
2022
Q2 		$4.06M Buy
407,563
+289
+0.1% +$2.87K 0.09% 356
2022
Q1 		$4.04M Buy
+407,274
New +$4.02M 0.09% 333

Other funds holding OBIO

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

Radcliffe Capital Management's OBIO Position: Q3 2022 in Review

Radcliffe Capital Management sold out of Orchestra BioMed (OBIO) in Q3 2022, closing a stake of 407,563 shares — an estimated $4.06M sold.

Radcliffe Capital Management first reported a position in OBIO in Q1 2022 and held it in 2 quarters. The position peaked at $4.06M in Q2 2022. 23 funds tracked by Wall St. Rank hold OBIO as of Q3 2022.

  • Radcliffe Capital Management reported no remaining Orchestra BioMed position as of Q3 2022 after selling out during the quarter.
  • Radcliffe Capital Management sold 407,563 Orchestra BioMed shares in Q3 2022, an estimated $4.06M.
  • Radcliffe Capital Management first reported a position in Orchestra BioMed in Q1 2022 and held it in 2 quarters.
  • Radcliffe Capital Management's Orchestra BioMed position peaked at $4.06M in Q2 2022.
  • 23 funds tracked by Wall St. Rank held Orchestra BioMed as of Q3 2022.

Based on Radcliffe Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.